Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

责任编辑：小浪快报 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 进一步统计，近3个月内该股累计发生1笔大宗交易，合计成交金额为940.8万元。该股近5个交易日累计 下跌1.99%，主力资金合计净流出234.49万元。 12月26日，睿昂基因收跌1.36%，收盘价为26.12元，发生1笔大宗交易，合计成交量40万股，成交金额 940.8万元。 第1笔成交价格为23.52元，成交40.00万股，成交金额940.80万元，溢价率为-9.95%，买方营业部为国元 证券股份有限公司深圳益田路证券营业部，卖方营业部为东海证券股份有限公司深圳深南大道证券营业 部。 ...

12月26日，睿昂基因大宗交易成交40万股，成交额940.8万元，占当日总成交额的35.93%，成交价23.52 元，较市场收盘价26.12元折价9.95%。 | 交易日期 | | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 025-12-26 | 容易基因 | 688217 | 23.52 940.8 | 40 | 零部長薪盤當落燈 | 藝禮攝發驚鬼露 | | ya | ...

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]

Core Viewpoint - Ruiang Gene experienced a decline of 5.44% in stock price on November 21, with a trading volume of 32.91 million yuan. The financing data indicates a net buying of 2.18 million yuan on that day, while the total financing and securities balance reached 59.36 million yuan, reflecting a low financing balance compared to historical levels [1][2]. Group 1: Company Overview - Ruiang Gene Technology Co., Ltd. was established on February 17, 2012, and went public on May 17, 2021. The company specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments and reagents, primarily focusing on blood diseases, solid tumors, and infectious diseases [2]. - The revenue composition of Ruiang Gene includes 84.23% from self-produced reagents, 6.86% from testing services, 6.63% from purchased reagents, 1.28% from research services, and 1.00% from other sources [2]. Group 2: Financial Performance - For the period from January to September 2025, Ruiang Gene reported an operating income of 139 million yuan, a year-on-year decrease of 26.64%. The net profit attributable to the parent company was -5.62 million yuan, reflecting a significant year-on-year decline of 198.14% [2]. - As of September 30, the number of shareholders for Ruiang Gene was 4,715, an increase of 0.62% from the previous period, while the average circulating shares per person decreased by 0.61% to 11,846 shares [2]. Group 3: Dividend Information - Ruiang Gene has distributed a total of 19.44 million yuan in dividends since its A-share listing [3].

Core Viewpoint - The company held its fourth extraordinary general meeting of shareholders on November 14, 2025, where all proposed resolutions were approved without any objections [2][5][6]. Group 1: Meeting Details - The meeting was convened by the board of directors and chaired by the chairman, Gao Shangxian, using a combination of on-site and online voting methods [3]. - All eight current directors attended the meeting, along with the company secretary and other executives [4]. - The total share capital as of the meeting date was 55,855,896 shares, with 669,621 shares in the repurchase account not entitled to vote [2]. Group 2: Resolutions and Voting - The main resolution discussed was the reappointment of the accounting firm, which was approved [5]. - All resolutions presented at the meeting received approval, and separate voting was conducted for minority investors [6]. Group 3: Legal Verification - The meeting was witnessed by lawyers from Shanghai Jintiancheng Law Firm, who confirmed that the meeting's procedures complied with relevant laws and regulations [6]. Group 4: Fund Utilization Announcement - The company announced its decision to use its own funds to pay for project expenses and subsequently replace these with raised funds, as approved in the eighth meeting of the third board of directors on November 13, 2025 [7][13]. - The total amount raised from the initial public offering was RMB 256.038 million, with a net amount of RMB 194.797 million after deducting issuance costs [7]. - The company plans to improve operational efficiency and reduce financial costs by using its own funds for project payments, which will be replaced by raised funds within six months [9][13]. Group 5: Operational Procedures - The company established a clear process for payment and replacement of funds, ensuring compliance with internal approval procedures and regulatory requirements [10][11]. - The company will maintain a detailed ledger of transactions related to the replacement of funds to ensure proper usage for the intended projects [11]. Group 6: Impact on Operations - The decision to use self-funds for project payments is expected to enhance the efficiency of fund utilization and project implementation without affecting the normal operation of the fundraising projects [13].

Core Viewpoint - Ruiang Gene announced the approval of a proposal to use its own funds to pay for fundraising project expenses and to replace these with equivalent amounts from raised funds [2] Group 1: Company Actions - The company will hold its third board meeting on November 13, 2025, to discuss the proposal [2] - The proposal allows the company and its subsidiaries to use self-owned funds for project expenses during the implementation period [2] - The equivalent amount of funds used will be transferred from the fundraising account to the company's own funds account, treating this amount as project usage funds [2]

国泰海通证券股份有限公司 关于上海睿昂基因科技股份有限公司使用自有资金支付 募投项目所需资金并以募集资金等额置换的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐机构"）作为承 接上海睿昂基因科技股份有限公司（以下简称"公司"、"上市公司"、"睿昂基因"） 首次公开发行股票并在科创板上市持续督导工作的保荐机构，根据《证券发行上 市保荐业务管理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股 票上市规则》等法律法规和规范性文件的要求，对使用自有资金支付募投项目所 需资金并以募集资金等额置换进行了核查，核查情况及核查意见如下： 一、募集资金基本情况 三、公司使用自有资金支付募投项目所需资金并以募集资金等额置换的原因 根据《上市公司募集资金监管规则》第十五条第二款的规定"募集资金投资 项目实施过程中，原则上应当以募集资金直接支付，在支付人员薪酬、购买境外 产品设备等事项中以募集资金直接支付确有困难的，可以在以自筹资金支付后六 个月内实施置换"。公司在募投项目实施期间，公司存在使用自有资金支付募投 项目所需资金并拟以募集资金等额置换的情形，具体原因如下： （一）公司募投项目在实施过程中需要支 ...

证券代码：688217 证券简称：睿昂基因 公告编号：2025-053 上海睿昂基因科技股份有限公司 关于使用自有资金支付募投项目所需资金并以 募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海睿昂基因科技股份有限公司（以下简称"公司"）于 2025 年 11 月 13 日 召开第三届董事会第八次会议，审议通过了《关于使用自有资金支付募投项目 所需资金并以募集资金等额置换的议案》，同意公司（含实施募投项目的子公 司，下同）在募投项目实施期间，根据实际情况使用自有资金支付募投项目所 需资金，并以募集资金等额置换，即从募集资金专户划转等额资金至公司自有 资金账户，该部分等额置换资金视同募投项目使用资金。保荐机构国泰海通证 券股份有限公司（以下简称"保荐机构"）对本事项出具了无异议的核查意见。 上述事项在董事会审批权限范围内，无需提交股东会审议。具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海睿昂基因科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕112 ...

法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2025 年第四次临时股东会的 上海市锦天城律师事务所 关于上海睿昂基因科技股份有限公司 2025 年第四次临时股东会的 法律意见书 案号：01G20231416 致：上海睿昂基因科技股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受上海睿昂基因科技股份有 限公司（以下简称"公司"）委托，就公司召开 2025 年第四次临时股东会（以下 简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以下简称《" 公 司法》"）、《上市公司股东会规则》（以下简称《" 股东会规则》"）等法律、法规 和其他规范性文件以及《上海睿昂基因科技股份有限公司章程》（以下简称《" 公 司章程》"）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履 ...